Astal Lab

Which are the latest news on Astal Lab?

Why is Astal Laboratories Ltd falling/rising?

As of 01-Aug, Astal Laboratories Ltd's stock price is rising to Rs 84.58, up 3.1%, supported by strong fundamentals and positive financial indicators despite recent declines in investor participation. The stock has shown significant long-term growth, outperforming its sector and trading above key moving averages.

As of 01-Aug, Astal Laboratories Ltd's stock price is rising, currently at Rs 84.58, reflecting an increase of Rs 2.54 or 3.1%. This upward movement is supported by several factors. Today, the stock outperformed its sector by 2.27% and reached an intraday high of Rs 85.85, which is a 4.64% increase. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price performance.<BR><BR>Despite a decline of 3.93% over the past month and a year-to-date drop of 2.61%, the stock has shown significant long-term growth, with a remarkable increase of 214.54% over the past three years and 745.80% over the last five years. The company's strong financial health is also a contributing factor, as it has a robust EBIT to Interest ratio of 11.09, indicating its ability to service debt effectively. Furthermore, the company's net sales have grown at an impressive annual rate of 287.90%, and operating profit has increased by 55.70%. <BR><BR>While there has been a decrease in investor participation, with delivery volume falling by 25.53% against the 5-day average, the overall positive financial indicators and the stock's attractive valuation compared to peers suggest that the recent rise in stock price is supported by strong fundamentals.

How big is Astal Lab?

As of 10th June, Astal Laboratories Ltd has a market capitalization of 332.00 Cr, with recent net sales of 209.76 Cr and a net profit of 12.78 Cr over the last three quarters.

As of 10th June, <BR><BR>Market Cap: Astal Laboratories Ltd has a market capitalization of 332.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest three quarters is 209.76 Cr, while the sum of Net Profit for the same period is 12.78 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 35.99 Cr, and Total Assets are valued at 63.34 Cr.

Who are in the management team of Astal Lab?

The management team of Astal Lab includes Sudhir Kumar Parasrampuria (Chairman and Managing Director), Gautam Lhila (Non Executive Independent Director), Manoj Kumar Poddar (Non Executive Independent Director), and Parwati Parasrampuria (Non Executive Director).

The management team of Astal Lab includes the following individuals:<BR><BR>1. Sudhir Kumar Parasrampuria - Chairman and Managing Director<BR>2. Gautam Lhila - Non Executive Independent Director<BR>3. Manoj Kumar Poddar - Non Executive Independent Director<BR>4. Parwati Parasrampuria - Non Executive Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

Who are the peers of the Astal Lab?

Astal Lab's peers include Balgopal Commer., Agribio Spirits, Sakuma Exports, Vikas Lifecare, Sicagen India, Gautam Exim, and HP Telecom. Astal Lab shows excellent growth and good capital structure, with a 1-year return of -14.83%, while Agribio Spirits leads with a 48.92% return.

Peers: The peers of Astal Lab are Balgopal Commer., Agribio Spirits, Sakuma Exports, Vikas Lifecare, Sicagen India, Gautam Exim, and HP Telecom.<BR><BR>Quality Snapshot: Excellent management risk is observed at HP Telecom, while Average management risk is found at Balgopal Commer., Astal Lab, Sakuma Exports, and Sicagen India. Below Average management risk is present at Agribio Spirits, Vikas Lifecare, Gautam Exim, and the rest. Astal Lab shows Excellent growth, while Good growth is noted at Sicagen India, and Average growth is seen at Balgopal Commer., Sakuma Exports, and the rest. Below Average growth is reported for Agribio Spirits, Vikas Lifecare, and Gautam Exim. Good capital structure is held by Balgopal Commer., Astal Lab, Agribio Spirits, Sakuma Exports, while Below Average capital structure is noted for Vikas Lifecare, Sicagen India, Gautam Exim, and HP Telecom.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Agribio Spirits at 48.92%, while the lowest is Sakuma Exports at -46.46%. Astal Lab's 1-year return is -14.83%, which is higher than Sakuma Exports but lower than Agribio Spirits. Additionally, Vikas Lifecare, Sakuma Exports, and Sicagen India have negative six-month returns.

What does Astal Lab do?

Astal Laboratories Limited manufactures and sells pharmaceutical intermediates and bulk drugs, classified as a Micro Cap company. As of March 2026, it reported net sales of 134 Cr and a net profit of 8 Cr.

Overview: <BR>Astal Laboratories Limited is engaged in the manufacture and sales of pharmaceutical intermediates and bulk drugs, operating within the Trading & Distributors industry and classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 1993 under the name Macro International Limited. It underwent a takeover under SEBI guidelines in 2022, leading to a change in its main business focus. The name was changed to Astal Laboratories Limited in May 2024. The most recent quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 134 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 8 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 332 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 40.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.15 <BR>Return on Equity: 4.41% <BR>Price to Book: 0.94 <BR><BR>Contact Details: <BR>Address: 24/147 Ground Floor, Plaza Kalpana Birhana Road Kanpur Uttar Pradesh : 208001 <BR>Tel: 91-512-2332481 <BR>Email: miel1@rediffmail.com <BR>Website: http://www.miel.co.in

Should I buy, sell or hold Astal Laboratories Ltd?

Are Astal Laboratories Ltd latest results good or bad?

Astal Laboratories Ltd's latest results show strong revenue growth and a significant increase in net profit, but concerns arise from sharply declining profit margins and negative operating cash flow, indicating challenges in profitability and cash management. Overall, the results reflect good growth potential but raise red flags for investors.

Astal Laboratories Ltd's latest results present a mixed picture. On one hand, the company achieved a remarkable net profit of ₹7.68 crores in Q4 FY26, which is a significant increase of 225.42% compared to the previous quarter. Additionally, revenue surged by 156.60% quarter-on-quarter to ₹134.05 crores, indicating strong topline growth.<BR><BR>However, there are notable concerns regarding profitability. The operating margin has contracted sharply from 17.81% in the same quarter last year to just 7.60%, and the profit after tax (PAT) margin has halved from 11.67% to 5.73%. This suggests that while the company is growing its revenue, it is facing challenges in maintaining profitability, possibly due to rising costs or pricing pressures.<BR><BR>Furthermore, the company's cash flow situation raises red flags, as it reported negative operating cash flow of ₹12.00 crores for FY25, indicating that profits are not translating into cash. This disconnect could limit financial flexibility moving forward.<BR><BR>In summary, while Astal Laboratories has demonstrated impressive revenue growth and improved net profit, the significant margin compression and negative cash flow present serious challenges that investors should consider. Overall, the results can be seen as good in terms of growth but concerning regarding profitability and cash flow management.

When is the next results date for Astal Laboratories Ltd?

The next results date for Astal Laboratories Ltd is 30 May 2026.

The next results date for Astal Laboratories Ltd is scheduled for 30 May 2026.

Is Astal Lab overvalued or undervalued?

As of December 3, 2025, Astal Lab is considered a very attractive investment due to its undervalued status, highlighted by a PE ratio of 9.14, a PEG ratio of 0.10, and a strong ROCE of 27.45%, despite recent underperformance compared to the Sensex, while its long-term returns significantly exceed those of the index.

As of 3 December 2025, the valuation grade for Astal Lab has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently deemed undervalued, supported by a PE ratio of 9.14, an EV to EBIT of 6.96, and an impressive ROCE of 27.45%. In comparison to peers, PTC India, which is also rated very attractive, has a lower PE ratio of 7.21, while Elitecon International is categorized as very expensive with a PE ratio of 197.75, highlighting Astal Lab's relative affordability.<BR><BR>Astal Lab's valuation metrics, particularly its PEG ratio of 0.10, suggest significant growth potential compared to its price, further reinforcing the undervaluation narrative. Despite recent underperformance relative to the Sensex over the past month and year, the long-term outlook remains strong, with a remarkable 10-year return of 281.82%, significantly outpacing the Sensex's 228.77%. This combination of robust financial ratios and favorable peer comparisons positions Astal Lab as a compelling investment opportunity.

How has been the historical performance of Astal Lab?

Astal Lab experienced significant growth from March 2023 to March 2025, with net sales rising from 3.43 Cr to 64.23 Cr and profit after tax increasing from 0.02 Cr to 8.93 Cr. However, cash flow from operating activities remained negative at -12.00 Cr in March 2025.

Answer:<BR>The historical performance of Astal Lab shows significant growth in net sales and profitability over the years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Astal Lab's net sales increased dramatically from 3.43 Cr in March 2023 to 64.23 Cr in March 2025, marking a substantial growth trajectory. The total operating income followed a similar trend, rising from 3.43 Cr in March 2023 to 64.23 Cr in March 2025. The company's total expenditure also increased, but at a slower pace, reaching 51.46 Cr in March 2025 from 3.56 Cr in March 2023. This led to an operating profit (PBDIT) of 12.90 Cr in March 2025, a significant improvement from a loss of 0.13 Cr in March 2023. Consequently, profit before tax surged to 11.98 Cr in March 2025, compared to just 0.03 Cr in March 2023, resulting in a profit after tax of 8.93 Cr in March 2025, up from 0.02 Cr in March 2023. The company's total assets grew to 63.34 Cr in March 2025 from 9.91 Cr in March 2023, while total liabilities increased to 63.34 Cr from 9.91 Cr in the same period. However, cash flow from operating activities remained negative, at -12.00 Cr in March 2025, indicating challenges in cash management despite the growth in sales and profits.

Who are the top shareholders of the Astal Lab?

The top shareholders of Astal Lab are Aceso Research Labs LLP with 19.93%, followed by Radha Krishna Doradla at 3.56%. Individual investors collectively own 73.8%, with no institutional holdings or pledged promoter shares.

The top shareholders of Astal Lab include Aceso Research Labs LLP, which holds the largest stake at 19.93%. Following that, the highest public shareholder is Radha Krishna Doradla, with a 3.56% share. Additionally, individual investors collectively hold a significant portion of the company at 73.8%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

What is the technical trend for Astal Lab?

As of May 27, 2025, Astal Lab's technical trend is mildly bearish, with bearish signals from the weekly MACD and daily moving averages, although the weekly KST shows mild bullishness and Bollinger Bands indicate potential volatility.

As of 27 May 2025, the technical trend for Astal Lab has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The RSI on a monthly basis is bearish, suggesting weakness in price action. Daily moving averages are bearish, reinforcing the negative sentiment. However, the KST on a weekly basis is mildly bullish, which introduces some mixed signals. Bollinger Bands show a sideways trend weekly but are mildly bullish monthly, indicating potential for volatility. Overall, the current stance is mildly bearish with weak momentum, driven primarily by the bearish indicators in MACD and moving averages.

Has Astal Lab declared dividend?

No Dividend History Available